CLSD · As filed with the SEC
Clearside Biomedical cash flow statement, by fiscal year
The statement as Clearside Biomedical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Operating activities | ||||
| Net loss | (34,352,000) | (32,485,000) | (32,947,000) | (376,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Non-cash interest expense on liability related to the sales of future royalties, net of issuance costs accretion | 9,779,000 | 9,361,000 | 3,339,000 | — |
| Depreciation | 226,000 | 67,000 | 145,000 | 178,000 |
| Share-based compensation expense | 4,513,000 | 4,202,000 | 4,884,000 | 5,054,000 |
| Change in fair value of warrant liabilities | (3,635,000) | — | — | — |
| Issuance costs allocated to warrant liabilities | 787,000 | — | — | — |
| Amortization and accretion of available-for-sale investments, net | (339,000) | — | — | — |
| Gain on termination of operating lease | 0 | 0 | (55,000) | — |
| Loss on disposal of fixed assets | 0 | 0 | 33,000 | 0 |
| Amortization and accretion on available-for-sale investments, net | — | — | — | 0 |
| Gain on extinguishment of debt | — | 0 | 0 | (998,000) |
| Non-cash interest expense | — | — | 0 | 0 |
| Accretion of debt discount | — | — | 0 | 0 |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable, prepaid expenses and other current assets | (51,000) | (220,000) | 10,420,000 | (10,869,000) |
| Other assets and liabilities | (118,000) | 456,000 | (83,000) | (155,000) |
| Accounts payable and accrued liabilities (includes $248 and $82 to a related party for the year ended December 31, 2024 and 2023, respectively) | (1,433,000) | 614,000 | 694,000 | 681,000 |
| Deferred revenue | — | — | 205,000 | (5,000,000) |
| Deferred revenue | (75,000) | (130,000) | — | — |
| Net cash used in operating activities | (24,698,000) | (18,135,000) | (13,365,000) | (10,733,000) |
| Investing activities | ||||
| Maturities of available-for-sale-investments | — | — | — | 0 |
| Purchase of short-term investments | (16,911,000) | — | — | — |
| Maturity of short-term investments | 17,250,000 | — | — | — |
| Acquisition of property and equipment | (977,000) | (1,777,000) | (246,000) | 0 |
| Net cash used in investing activities | (638,000) | (1,777,000) | (246,000) | 0 |
| Financing activities | ||||
| Proceeds from issuance of common stock and warrants in registered direct offering, net of issuance costs | 13,860,000 | — | — | — |
| Proceeds from royalty purchase and sale agreement, net of $1,862 of issuance costs | 0 | 0 | 30,638,000 | — |
| Payments on royalty purchase and sale agreement | 0 | (1,350,000) | — | — |
| Proceeds from at-the-market sales agreement, net of issuance costs | 2,529,000 | 1,666,000 | 566,000 | 12,205,000 |
| Proceeds from registered direct offering, net of issuance costs | — | — | — | 11,078,000 |
| Proceeds from private placement, net of issuance costs | — | — | — | 0 |
| Proceeds from registered direct offering, net of issuance costs | — | 0 | 0 | — |
| Proceeds from shares issued under employee stock purchase plan | 35,000 | 65,000 | 112,000 | 111,000 |
| Proceeds from exercise of stock options | 12,000 | 33,000 | 17,000 | 388,000 |
| Proceeds from issuance of long-term debt | — | — | 0 | 0 |
| Principal payments made on long-term debt | — | — | 0 | 0 |
| Net cash provided by financing activities | 16,436,000 | 414,000 | 31,333,000 | 23,782,000 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (8,900,000) | (19,498,000) | 17,722,000 | 13,049,000 |
| Cash, cash equivalents and restricted cash, beginning of period | 28,920,000 | 48,418,000 | 30,696,000 | 17,647,000 |
| Cash, cash equivalents and restricted cash, end of period | 20,020,000 | 28,920,000 | 48,418,000 | 30,696,000 |
| Supplemental disclosure | ||||
| Interest paid | — | — | 0 | 0 |
| accounts payable and accrued liabilities | — | — | 282,000 | — |
| Purchase of property and equipment in accounts payable and accrued liabilities | 9,000 | 531,000 | — | — |
| Forgiveness of PPP Loan and accrued interest | — | 0 | 0 | 998,000 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||||
| Cash and cash equivalents | — | — | — | 30,436,000 |
| Restricted cash ($100 as of December 31, 2021 is recorded in other current assets) | — | — | — | 260,000 |
| Cash, cash equivalents and restricted cash, end of period | — | — | — | 30,696,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.